v3.26.3
Segment Report
9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Segment Report

Note 9 – Segment Report

 

The Company’s Chief Executive Officer serves as the Chief Operating Decision Maker (“CODM”). The CODM evaluates financial performance and makes resource allocation decisions based on the operating results of the Company’s reportable segments.

 

Effective October 1, 2025, the Company operates through two reportable segments: (i) premium nutritional supplements, and (ii) pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. Prior to October 1, 2025, the Company operated as a single reportable segment. Accordingly, comparative segment information for the three and nine months ended September 30, 2025 has not been presented.

 

Premium Nutritional Supplements

 

This segment includes all activities related to the commercialization and sale of the Company’s Nugevia product line. Activities within this segment primarily consist of marketing, distribution, sales, customer support, and related supply chain management associated with Nugevia products.

 

Pharmaceutical Operations

 

This segment includes all activities related to the research, development, and regulatory advancement of JOTROL™, the Company’s proprietary resveratrol-based therapeutic candidate, which is being developed to address unmet medical needs and improve patient outcomes and PharmAla’s Ala-002, a proprietary, investigational, next-generation MDMA formulation consisting of a non-racemic mixture of MDMA enantiomers. Activities within this segment primarily consist of clinical development, regulatory, manufacturing development, intellectual property protection, and related research and development functions.

 

The CODM assesses segment performance and allocates resources based on segment operating loss (income), which represents the primary measure of profit or loss reviewed. The CODM does not evaluate segments using discrete asset or liability information.

 

Allocation Methodology

 

Expenses are attributed to each reportable segment based on the nature of the activity and the function to which the expense relates. Costs that are directly identifiable with a specific segment are recorded to that segment. Selling, general and administrative expenses that benefit both segments are allocated using reasonable and consistently applied methodologies that reflect the estimated level of effort or resources consumed by each segment. These allocation methodologies may include time and effort analyses, headcount, relative revenue, or other activity-based measures, depending on the underlying cost driver.

 

 

The allocation methodologies are reviewed periodically and refined as necessary to reflect changes in the business. The Company believes such allocations are reasonable and consistent with the manner in which the CODM evaluates segment performance and makes resource allocation decisions.

 

Corporate and other expenses consist primarily of public company costs (including board, investor relations, and SEC reporting expenses), certain executive compensation, certain stock-based compensation, interest income (expense), other income (expense), and income taxes. These costs are not allocated to reportable segments because they are not included in the measures reviewed by the CODM for purposes of assessing segment performance.

 

Segment information for the three months ended September 30, 2026 is presented below:

  

   Pharmaceutical
Operations
   Premium
Nutritional
Supplements
   Total
Reportable
Segments
   Corporate
/ Other
   Total 
Revenue   -    13,942    13,942    -    13,942 
Cost of goods sold   -    4,334    4,334    -    4,334 
Research and development   3,892,387    -    3,892,387    -    3,892,387 
General and administrative   260,685    245,753    506,438    1,406,489    1,912,927 
Segment operating loss   (4,153,072)   (236,145)   (4,389,217)   (1,406,489)   (5,795,706)
Other income (expense), net   -    -    -    (1,428,364)   (1,428,364)
Net loss   (4,153,072)   (236,145)   (4,389,217)   (2,834,853)   (7,224,070)

 

Segment information for the nine months ended September 30, 2026 is presented below:

 

   Pharmaceutical
Operations
   Premium
Nutritional
Supplements
   Total
Reportable
Segments
   Corporate
/ Other
   Total 
Revenue   -    56,839    56,839    -    56,839 
Cost of goods sold   -    11,877    11,877    -    11,877 
Research and development   4,903,789    -    4,903,789    -    4,903,789 
General and administrative   966,216    1,102,279    2,068,495    3,574,329    5,642,824 
Segment operating loss   (5,870,005)   (1,057,317)   (6,927,322)   (3,574,329)   (10,501,651)
Other income (expense), net   -    -    -    (1,058,774)   (1,058,774)
Net loss   (5,870,005)   (1,057,317)   (6,927,322)   (4,633,103)   (11,560,425)